Descripción de la empresa
Nexalin Technology, Inc. operates as a specialized entity within the healthcare sector, specifically focusing on the medical devices industry. The company is dedicated to designing and developing neurostimulation products aimed at treating mental health conditions in the United States and China markets. Its primary offering, Generation 1, represents an easy-to-administer medical device that leverages bioelectronic medical technology to address anxiety. As of the latest reporting period, the company holds a market capitalization of $7.24M and reported a trailing twelve-month revenue of $301,647. While the employee count is listed as N/A, the valuation metrics provide context for its scale: a market cap of $7.24M relative to revenue of $301,647 indicates a capitalization that is significantly higher than its current sales run-rate, suggesting the market is pricing in substantial future growth potential or speculative expectations regarding the commercialization of its neurostimulation technology rather than current operational profitability.
Salud financiera
The company reported a trailing twelve-month revenue of $301,647, yet the net income for the same period was a significant loss of $-8,222,181, while EBITDA stood at $-8,369,344. The substantial gap between the modest revenue figure and the massive negative net income reveals a cost structure characterized by high operating expenses that far exceed current sales, a common trait in early-stage biotech or device development phases where research, development, and regulatory compliance costs are front-loaded. Free cash flow for the trailing twelve months was $-1,950,561, indicating that the company is burning cash to fund its operations and product development, which limits its immediate financial flexibility and reliance on external capital sources. The gross margin stands at 79.7%, which suggests that the cost of goods sold is relatively low compared to revenue, but the operating margin of -1403.9% and the profit margin of 0.0% highlight severe operational inefficiencies or high overhead costs relative to sales volume. On the balance sheet, the company holds $3.72M in cash with no reported debt, creating a situation where total cash exceeds total debt, though the debt-to-equity ratio is N/A due to the absence of traditional debt instruments. The current ratio is 4.84, which indicates a strong position in short-term liquidity, as the company possesses current assets sufficient to cover its current liabilities nearly five times over. Return on Equity is -221.5% and Return on Assets is -118.4%, metrics that reveal that management is currently generating negative returns on both shareholder equity and the asset base, reflecting the challenges of scaling a product from development to commercialization without yet achieving break-even profitability.
Evaluación de valoración
The trailing P/E ratio is N/A because the company is unprofitable, while the forward P/E is reported as -0.90, a negative figure that implies the market is anticipating a potential turnaround or is valuing the company based on non-traditional earnings metrics that are not yet realized. The price-to-book ratio is 1.80, indicating that the market values the company at a premium of 80% over its book value, which often reflects the intangible value of its intellectual property, patents, and the potential future cash flows from its neurostimulation devices. The price-to-sales ratio is 24.01, and the EV/EBITDA is -0.42; these alternative valuation metrics suggest that investors are willing to pay a high multiple of sales for the company despite its lack of earnings, likely betting on the successful market penetration of Generation 1. The stock has traded within a 52-week range with a high of $2.31 and a low of $0.34, meaning the current price sits at a level that requires calculation relative to the recent volatility but is structurally positioned below the 52-week high of $2.31 given the recent performance trajectory. The beta value is 4.23, which signifies that the stock price is highly volatile and expected to fluctuate with 4.23 times the magnitude of the broader market movements, presenting a high-risk profile suitable only for investors with a high tolerance for price swings.
Growth & Income
Revenue growth year-over-year is reported at 532.5%, while earnings growth year-over-year is N/A due to the company's ongoing losses; this disparity implies that the company is expanding its top line rapidly but has not yet translated that revenue expansion into profitability. The company does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning there is no cash distribution to shareholders. Consequently, the company reinvests all available earnings, or rather all available cash flow, back into the business to fund research, development, and market expansion rather than paying dividends to income-seeking investors. The overall growth and income profile is characterized by explosive revenue expansion coupled with significant cash burn and a complete absence of dividend income, positioning the asset as a pure growth play dependent on future commercial success.